Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 237

Similar articles for PubMed (Select 23992517)

1.

A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.

Hess CN, Al-Khatib SM, Granger CB, Lopes R.

Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105-14. doi: 10.1586/14779072.2013.824181. Epub 2013 Sep 2. Review.

PMID:
23992517
2.

Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice.

Tanislav C, Milde S, Schwartzkopff S, Misselwitz B, Sieweke N, Kaps M.

BMC Res Notes. 2015 Jun 25;8(1):262. doi: 10.1186/s13104-015-1237-2.

3.

Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.

Ment J.

Vasc Health Risk Manag. 2015 Jun 10;11:317-32. doi: 10.2147/VHRM.S79065. eCollection 2015. Review.

4.

Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.

Singh SM, Wijeysundera HC.

Curr Cardiol Rep. 2015 Aug;17(8):618. doi: 10.1007/s11886-015-0618-4.

PMID:
26081245
6.

Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?

Akinboboye O.

J Multidiscip Healthc. 2015 May 18;8:217-28. doi: 10.2147/JMDH.S74529. eCollection 2015. Review.

7.

Assessment of the Anticoagulation Activity of Apixaban - Reply.

Silvain J.

Circ J. 2015 Jun 25;79(7):1642. doi: 10.1253/circj.CJ-15-0487. Epub 2015 May 29. No abstract available.

8.

Assessment of the Anticoagulation Activity of Apixaban.

Gonçalves LR, Araújo F.

Circ J. 2015 Jun 25;79(7):1641. doi: 10.1253/circj.CJ-15-0399. Epub 2015 May 29. No abstract available.

9.

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.

Acharya T, Deedwania P.

Core Evid. 2015 May 28;10:63-73. doi: 10.2147/CE.S61441. eCollection 2015. Review.

10.

Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.

Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Rönquist-Nii Y, Söderblom L, Östlund AY, Pohanka A, Antovic J, Malmström RE.

Thromb Res. 2015 Jul;136(1):148-53. doi: 10.1016/j.thromres.2015.04.030. Epub 2015 Apr 30.

PMID:
25981142
11.

Might apixaban be the optimal oral anticoagulant for haemophiliacs with atrial fibrillation?

Aguilar C.

Haemophilia. 2015 Jul;21(4):e338-40. doi: 10.1111/hae.12709. Epub 2015 May 4. No abstract available.

PMID:
25939786
12.

Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.

Diener HC, Halperin JL, Fox K, Hankey GJ.

Int J Clin Pract. 2015 Jul;69(7):743-56. doi: 10.1111/ijcp.12631. Epub 2015 Apr 9.

PMID:
25854636
13.

Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany.

Krejczy M, Harenberg J, Wehling M, Obermann K, Lip GY.

Biomed Res Int. 2015;2015:876923. doi: 10.1155/2015/876923. Epub 2015 Mar 17.

14.

[Why NAO: Know How. Why and how to choose the new oral anticoagulant in cardiological clinical practice].

Rossini R, Pecora D, Ferlini M, Gentile F, Moschini L, Pedrinazzi C, Ravizza P, Romano M, Canova P, Oliva F.

G Ital Cardiol (Rome). 2015 Mar;16(3):161-74. doi: 10.1714/1820.19826. Review. Italian.

PMID:
25837460
15.

A survey of the use of empiric novel anticoagulants during investigation of stroke.

van Gaal S, Carrier M, Rodriguez RA, Sharma M, Mallick R, Stotts G, Dowlatshahi D.

Can J Neurol Sci. 2015 Mar;42(2):135-7. doi: 10.1017/cjn.2015.14. No abstract available.

PMID:
25804250
16.

Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP.

Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28. Review.

PMID:
25773559
17.

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR; ROCKET AF Steering Committee and Investigators.

Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.

PMID:
25749644
18.

[Effective anticoagulation also in advanced age].

Zimmermann W.

MMW Fortschr Med. 2015 Feb 19;157(3):72. doi: 10.1007/s15006-015-2717-y. German. No abstract available.

PMID:
25743684
19.

Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.

Ferreira J, Mirco A.

Rev Port Cardiol. 2015 Mar;34(3):179-91. doi: 10.1016/j.repc.2014.08.008. Epub 2015 Feb 27. English, Portuguese.

PMID:
25727748
20.

Venous thromboembolic event prevention in acute stroke: update on evidence and recommendations.

Anderson J.

Pract Neurol. 2015 Jun;15(3):160-163. doi: 10.1136/practneurol-2014-001035. Epub 2015 Feb 25. Review.

PMID:
25717093
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk